Sectoral Asset Management Inc. lessened its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Rating) by 3.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 63,500 shares of the company’s stock after selling 2,200 shares during the quarter. Sectoral Asset Management […]
Beam Therapeutics (NASDAQ:BEAM – Get Rating) had its price target reduced by Royal Bank of Canada from $50.00 to $42.00 in a research note issued to investors on Thursday morning, The Fly reports. A number of other analysts have also commented on the company. Sanford C. Bernstein initiated coverage on Beam Therapeutics in a report […]
Beam Therapeutics (NASDAQ:BEAM – Get Rating) had its price target cut by Royal Bank of Canada from $50.00 to $42.00 in a report issued on Thursday, The Fly reports. BEAM has been the subject of a number of other research reports. William Blair reiterated an outperform rating on shares of Beam Therapeutics in a research […]
Beam Therapeutics (NASDAQ:BEAM – Get Rating) had its target price decreased by Barclays from $45.00 to $41.00 in a report released on Thursday morning, The Fly reports. Several other research analysts have also commented on the company. William Blair restated an outperform rating on shares of Beam Therapeutics in a research report on Wednesday, March […]
Beam Therapeutics (NASDAQ:BEAM – Get Rating) had its price objective cut by stock analysts at Royal Bank of Canada from $50.00 to $42.00 in a note issued to investors on Thursday, The Fly reports. Royal Bank of Canada’s target price points to a potential upside of 18.74% from the stock’s previous close. A number of […]